Venturelab brings biotech start-ups to Boston

Schlieren ZH – The Venturelab Biotech 2024 initiative is enabling ten biotech start-ups to spend time in Boston. The aim is to establish contacts with potential partners and investors. The roadshow in the USA will take place from May 13 to 17.

Venturelab is organizing a trip for young entrepreneurs from the biotech sector to Boston from 13 to 17 May. The ten start-ups, which were selected by a jury from over 70 applications, will take part in the roadshow in Boston, one of the most important life science centers in the world, as so-called Venture Leaders Biotech, according to a press release from the start-up promoter. They will present themselves and their start-ups at a kick-off event on April 22 at the Swiss Biotech Day 2024 in Basel.

"The preparation for this roadshow, which is now in its 18th year, is a tribute to the quality of the innovations and start-ups that have already been part of this journey," Venturelab co-founder and CEO Jordi Montserrat is quoted as saying. "I can't wait to be part of this new edition and to support this new team in its international expansion."

These ten biotech start-ups are taking part this year: Adoram Therapeutics from Geneva, which develops small molecule therapies for the treatment of cancer, inflammation and other diseases. The Basel-based biopharma start-up Allegria Therapeutics is building up a differentiated portfolio of therapeutic approaches based on biological target molecules. Eviive from Zurich is working on novel biomarkers. inSEIT from Bern is dedicated to improving enzymes. Kylys Aesthetics from Geneva is focusing on a biocompatible dermal filler.

OBaris, based in Zurich, enables the painless administration of injectable drugs via a small, needle-free patch in the mouth. Shape Biopharmaceuticals, also based in Zurich, combines medical-chemical expertise with computer-aided protein design. TissueLabs in Manno TI specializes in advanced biofabrication. Well Science from Zurich wants to revolutionize the treatment of respiratory allergies. And Ymmunobio in Basel focuses on gastrointestinal cancers. ce/gba

View full article